ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

NBIX Neurocrine Biosciences Inc

130.37
-2.17 (-1.64%)
Last Updated: 14:56:26
Delayed by 15 minutes

Period:

Draw Mode:

Volume 275,618
Bid Price 130.30
Ask Price 130.43
News -
Day High 133.65

Low
89.04

52 Week Range

High
148.3699

Day Low 130.13
Company Name Stock Ticker Symbol Market Type
Neurocrine Biosciences Inc NBIX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-2.17 -1.64% 130.37 14:56:26
Open Price Low Price High Price Close Price Prev Close
132.65 130.13 133.65 132.54
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
10,111 275,618 $ 131.77 $ 36,317,332 - 89.04 - 148.3699
Last Trade Time Type Quantity Stock Price Currency
14:56:52 1 $ 130.3923 USD

Neurocrine Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
13.08B 99.51M - 1.89B 249.7M 2.51 52.39
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Neurocrine Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No NBIX Message Board. Create One! See More Posts on NBIX Message Board See More Message Board Posts

Historical NBIX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week136.22137.78130.13132.96707,017-5.85-4.29%
1 Month145.31145.42130.13137.38772,798-14.94-10.28%
3 Months141.73148.3699128.00136.95885,677-11.36-8.02%
6 Months112.05148.3699103.63129.06811,00318.3216.35%
1 Year103.13148.369989.04116.37763,71227.2426.41%
3 Years95.6214148.369971.875103.85760,43834.7536.34%
5 Years80.25148.369971.85102.63802,61050.1262.45%

Neurocrine Biosciences Description

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Your Recent History

Delayed Upgrade Clock